eligibility_summary
Eligible: new-onset idiopathic nephrotic syndrome with eGFR ≥90 ml/min/1.73 m². Exclude: recurrent hematuria (≥10 RBC/HPF), hypocomplementemia, persistent hypertension (>95th percentile), secondary NS, other kidney disease, relevant family history or monogenic NS, immunodeficiency/active infections, major lab abnormalities or severe organ disease, recent immunosuppressants, rituximab allergy, prior transplant (except cornea/hair), recent live vaccine, recent trial, or per investigator.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase 3 randomized pediatric trial comparing rituximab monotherapy vs standard glucocorticoids for new-onset nephrotic syndrome. Interventions: Rituximab (biologic, chimeric anti‑CD20 monoclonal antibody, 4 weekly 375 mg/m2 doses) versus prednisone/prednisolone regimen. Mechanisms: Rituximab depletes CD20+ B lymphocytes via complement activation, ADCC, and apoptosis, lowering pathogenic humoral activity and B–T cell crosstalk implicated in podocyte injury. Glucocorticoids (small-molecule steroid receptor agonists) broadly suppress immunity by inhibiting NF‑κB/AP‑1, reducing cytokines, T-cell proliferation, and B-cell antibody production. Targets: CD20+ B cells, downstream T cells, antigen-presenting cells, and cytokine pathways.